ArticleTrials2025
Study protocol for a multi-site randomized clinical trial of an intervention program to promote self-management among head and neck cancer survivors with lymphedema and fibrosis [PROMISE trial].
Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06125743 (Promoting Self-Management in Head and Neck Cancer Survivors With Lymphedema and Fibrosis [PROMISE Trial]), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Promoting Self-Management in Head and Neck Cancer Survivors With Lymphedema and Fibrosis [PROMISE Trial]
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLymphedema and fibrosis (LEF) secondary to head and neck cancer (HNC) treatment is a chronic process and a lifelong commitment to self-care. Although prospective data is lacking, a program of self-management may reduce LEF progression and minimize associated functional impairments and symptom burden. Barriers to long-term LEF self-care include lack of standardized self-care protocols as well as lack of LEF-related knowledge, skills, self-efficacy and adherence among HNC survivors. The objective of this study is to evaluate the effectiveness of a standardized lymphedema and fibrosis self-management program (LEF-SMP) in reducing LEF-associated symptom burden and functional deficits, thereby improving quality of life (QOL).
methodsWe will conduct a 3-year, multi-site, 3-arm parallel-group, randomized clinical trial (N = 204). The targeted population consists of adult HNC survivors. Eligible participants will be randomized to one of the following groups: Group 1, usual care; Group 2, in-person LEF-SMP; and Group 3, telehealth LEF-SMP. Recruitment, data collection, and study intervention will be conducted at two comprehensive medical centers including University of Pennsylvania Health System (Penn Medicine) and Vanderbilt-Ingram Cancer Center (VICC). Primary study endpoint is LEF severity; and secondary study endpoints include LEF-related symptom burden, functional impairments, QOL, LEF-related knowledge, skills, self-efficacy, and self-care adherence. All above-mentioned primary and secondary endpoints will be measured at the baseline (pre-intervention), and 3-, 6-, and 9-month post-intervention. DISCUSSION: This study will test whether the standardized lymphedema and fibrosis self-management program (LEF-SMP) has the ability to decrease the burden of LEF and its impact on HNC survivors. We anticipate that the intervention will improve LEF self-management, reduce LEF-associated symptom burden and functional impairments, and enhance QOL as well as LEF-related knowledge and skills in HNC survivors.
trial registrationThis study was registered on November 01, 2023, at ClinicalTrials.gov, a service of the US National Institute of Health (NCT06125743). The URL of the trial registry record: https://clinicaltrials.gov/study/NCT06125743 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.